Bradley DeNardo, Jennie Foster, Navin R. Pinto, Giselle Linda Saulnier Sholler, Kieuhoa Tran Vo, Ami Vijay Desai, Jessica Sun, Lars M. Wagner, Margaret E Macy, Rajen Mody, Javier E. Oesterheld, Thomas Cash, Roma Bhuta, Eveline Barbieri, Andrew DJ Pearson, Ludimila Cavalcante, Francis J. Giles, Rishi Ramesh Lulla. Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3ß) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):e22015-e22015.